retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Multi-target incretin-based therapeutics: The rise

Furthermore, the duration of treatment and the specifics of dietary interventions can substantially influence the results, as short-term interventions might not yield the same results as long-term interventions, and different dietary components could have varying effects on tumor growth and progression

Use a medical-grade insulated cooler with cold packs to keep the pen between 36F and 46F

You can supplement with Glutathione directly, or with its precursor, another antioxidant called NAC (N-Acetyl Cysteine)

So now with those other outcomes, like you said, Medicare is starting this pilot program to understand if these medications lead to overall cost savings